Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Neoplasms 44Prostatic Neoplasms 43Breast Neoplasms 38Neoplasm Metastasis 21Unspecified Adult Solid Tumor, Protocol Specific 19Lung Neoplasms 18Head and Neck Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Ovarian Neoplasms 15Advanced Solid Tumors 11Stomach Neoplasms 9Sarcoma 9Pancreatic Neoplasms 9Solid Tumor 8Melanoma 8Esophageal Neoplasms 8Carcinoma, Ovarian Epithelial 8Urinary Bladder Neoplasms 7Fallopian Tube Neoplasms 7Colorectal Neoplasms 7Small Cell Lung Carcinoma 6Salivary Gland Neoplasms 6Esthesioneuroblastoma, Olfactory 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Renal Cell 5Breast Neoplasms, Male 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4

Interventions

patritumab 1Gemcitabine 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Fibromatosis, Gingival, 2 × Docetaxel × Clear all
NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Hummingbird Bioscience

Phase 1 Active not recruiting
68 enrolled
GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡